Patents Assigned to Dart NeuroScience (Cayman) Ltd.
-
Patent number: 11186582Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: GrantFiled: November 25, 2019Date of Patent: November 30, 2021Assignee: Dart Neuroscience, (Cayman) LTD.Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Patent number: 10501465Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: GrantFiled: February 26, 2018Date of Patent: December 10, 2019Assignee: Dart Neuroscience (Cayman) Ltd.Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Patent number: 10376514Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: GrantFiled: October 18, 2018Date of Patent: August 13, 2019Assignee: Dart Neuroscience (Cayman) Ltd.Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael I. Weinhouse
-
Patent number: 10239882Abstract: The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: GrantFiled: November 3, 2015Date of Patent: March 26, 2019Assignee: DART NEUROSCIENCE (CAYMAN) LTD.Inventors: Amy Lynn Allan, James Breitenbucher, Laurent Gomez, Terence Patrick Keenan, Robert Lemus, Kiev Ly, Tami Jo Marrone
-
Patent number: 10105367Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: GrantFiled: December 29, 2016Date of Patent: October 23, 2018Assignee: DART NEUROSCIENCE (CAYMAN) LTD.Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael Weinhouse
-
Patent number: 10092575Abstract: Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: GrantFiled: November 17, 2016Date of Patent: October 9, 2018Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers
-
Patent number: 10053467Abstract: The invention provides a compound of formula I: wherein A1, A2, A3, R1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.Type: GrantFiled: April 4, 2017Date of Patent: August 21, 2018Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Alan Kaplan, Terence Keenan, Andrew McRiner
-
Patent number: 10040759Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.Type: GrantFiled: November 3, 2015Date of Patent: August 7, 2018Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Jillian Basinger, Brett Bookser, Mi Chen, Andrew Hudson, James Na, Joel Renick, Vincent Santora
-
Patent number: 9956213Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.Type: GrantFiled: May 23, 2017Date of Patent: May 1, 2018Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Jillian Basinger, Graeme Freestone, Varsha Gupta, Alan Kaplan, Chi Ching Mak, Benjamin Pratt, Vincent Santora, Dipanjan Sengupta, Lino Valdez
-
Patent number: 9956224Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: GrantFiled: December 29, 2016Date of Patent: May 1, 2018Assignee: DART NEUROSCIENCE (CAYMAN) LTD.Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael Weinhouse
-
Patent number: 9931318Abstract: The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.Type: GrantFiled: March 3, 2008Date of Patent: April 3, 2018Assignee: DART NEUROSCIENCE (CAYMAN) LTD.Inventors: Thomas M. Hallam, Tim Tully, Rusiko Bourtchouladze
-
Patent number: 9932345Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: GrantFiled: April 22, 2015Date of Patent: April 3, 2018Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Patent number: 9863934Abstract: The present invention provides methods for identifying cognitive enhancers able to enhance CREB pathway function. Cognitive enhancers identified in accordance with the invention can be used in rehabilitating an animal with cognitive dysfunction and for enhancing memory or normal cognitive performance (ability or function) in the animal.Type: GrantFiled: February 1, 2016Date of Patent: January 9, 2018Assignee: Dart Neuroscience (Cayman) Ltd.Inventors: Timothy P. Tully, Roderick E. M. Scott, Rusiko Bourtchouladze
-
Publication number: 20170334846Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.Type: ApplicationFiled: November 3, 2015Publication date: November 23, 2017Applicant: Dart Neuroscience (Cayman) Ltd.Inventors: Jillian Basinger, Brett Bookser, Mi Chen, Andrew Hudson, James Na, Joel Renick, Vincent Santora
-
Patent number: 9795591Abstract: The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.Type: GrantFiled: April 4, 2012Date of Patent: October 24, 2017Assignee: Dart Neuroscience (Cayman) Ltd.Inventors: Thomas M. Hallam, Tim Tully, Rusiko Bourtchouladze
-
Patent number: 9708334Abstract: The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, R4, R5 and X have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by GlyT1 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training; and treating other disorders, including pain and alcohol-dependence.Type: GrantFiled: April 22, 2015Date of Patent: July 18, 2017Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Jillian Basinger, Brett Bookser, Mi Chen, DeMichael Chung, Varsha Gupta, Andrew Hudson, Alan Kaplan, James Na, Joel Renick, Vincent Santora
-
Patent number: 9675605Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.Type: GrantFiled: September 23, 2015Date of Patent: June 13, 2017Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Jillian Basinger, Graeme Freestone, Varsha Gupta, Alan Kaplan, Chi Ching Mak, Benjamin Pratt, Vincent Santora, Dipanjan Sengupta, Lino Valdez
-
Patent number: 9650349Abstract: The invention provides a compound of formula I: wherein A1, A2, A3, R1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.Type: GrantFiled: May 11, 2015Date of Patent: May 16, 2017Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Alan Kaplan, Terence Keenan, Andrew McRiner
-
Patent number: 9624200Abstract: The invention includes a compound of formula I: wherein R1, Y, A, n, R4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.Type: GrantFiled: October 7, 2014Date of Patent: April 18, 2017Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Alan P. Kaplan, Terence P. Keenan, Michael I. Weinhouse, Mark E. Wilson, Andrew K. Lindstrom, William C. Ripka, Mi Chen
-
Patent number: 9573937Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.Type: GrantFiled: May 22, 2015Date of Patent: February 21, 2017Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Venkataiah Bollu, James Breitenbucher, Alan Kaplan, Robert Lemus, Andrew Lindstrom, Troy Vickers, Mark Wilson, James Zapf